BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pontes C, Zara C, Torrent-Farnell J, Obach M, Nadal C, Vella-Bonanno P, Ermisch M, Simoens S, Hauegen RC, Gulbinovic J, Timoney A, Martin AP, Mueller T, Nachtnebel A, Campbell S, Selke G, Bochenek T, Rothe CC, Mardare I, Bennie M, Fürst J, Malmstrom RE, Godman B. Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. Appl Health Econ Health Policy 2020;18:5-16. [PMID: 31696433 DOI: 10.1007/s40258-019-00527-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Tubic B, Marković-peković V, Jungić S, Allocati E, Godman B. Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications. Medicine Access @ Point of Care 2021;5:239920262110276. [DOI: 10.1177/23992026211027692] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Tafuri G, Bélorgey C, Favaretti C, Frénoy E, Giorgio F, Guardian M, Hebborn A, Houÿez F, Imbert J, Lacombe D, Garcia JL, Garrett Z, Petelos E, Saeterdal I, Schuurman A, Skjöldebrand AL, Strammiello V, Widmer D, Willemsen A, Hedberg N. The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes. Int J Technol Assess Health Care 2020;36:191-6. [PMID: 32317039 DOI: 10.1017/S0266462320000185] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Godman B, Hill A, Simoens S, Selke G, Selke Krulichová I, Zampirolli Dias C, Martin AP, Oortwijn W, Timoney A, Gustafsson LL, Voncina L, Kwon HY, Gulbinovic J, Gotham D, Wale J, Cristina Da Silva W, Bochenek T, Allocati E, Kurdi A, Ogunleye OO, Meyer JC, Hoxha I, Malaj A, Hierländer C, Sauermann R, Hamelinck W, Petrova G, Laius O, Langner I, Yfantopoulos J, Joppi R, Jakupi A, Greiciute-Kuprijanov I, Vella Bonanno P, Piepenbrink JH, de Valk V, Wladysiuk M, Marković-Peković V, Mardare I, Fürst J, Tomek D, Obach Cortadellas M, Zara C, Pontes C, McTaggart S, Laba TL, Melien Ø, Wong-Rieger D, Bae S, Hill R. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res 2021;21:527-40. [PMID: 33535841 DOI: 10.1080/14737167.2021.1884546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Elvira D, Obach M, Pontes C. Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies. BMC Health Serv Res 2021;21:814. [PMID: 34391431 DOI: 10.1186/s12913-021-06784-8] [Reference Citation Analysis]
5 Zampirolli Dias C, Godman B, Gargano LP, Azevedo PS, Garcia MM, Souza Cazarim M, Pantuzza LLN, Ribeiro-Junior NG, Pereira AL, Borin MC, de Figueiredo Zuppo I, Iunes R, Pippo T, Hauegen RC, Vassalo C, Laba TL, Simoens S, Márquez S, Gomez C, Voncina L, Selke GW, Garattini L, Kwon HY, Gulbinovic J, Lipinska A, Pomorski M, McClure L, Fürst J, Gambogi R, Ortiz CH, Canuto Santos VC, Araújo DV, Araujo VE, Acurcio FA, Alvares-Teodoro J, Guerra-Junior AA. Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics 2020;38:1165-85. [PMID: 32734573 DOI: 10.1007/s40273-020-00943-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
6 Godman B, Wladysiuk M, McTaggart S, Kurdi A, Allocati E, Jakovljevic M, Kalemeera F, Hoxha I, Nachtnebel A, Sauermann R, Hinteregger M, Marković-Peković V, Tubic B, Petrova G, Tachkov K, Slabý J, Nejezchlebova R, Krulichová IS, Laius O, Selke G, Langner I, Harsanyi A, Inotai A, Jakupi A, Henkuzens S, Garuolienė K, Gulbinovič J, Bonanno PV, Rutkowski J, Ingeberg S, Melien Ø, Mardare I, Fürst J, MacBride-Stewart S, Holmes C, Pontes C, Zara C, Pedrola MT, Hoffmann M, Kourafalos V, Pisana A, Banzi R, Campbell S, Wettermark B. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. Biomed Res Int 2021;2021:9996193. [PMID: 34676266 DOI: 10.1155/2021/9996193] [Reference Citation Analysis]
7 da Silva WC, Godman B, de Assis Acúrcio F, Cherchiglia ML, Martin A, Maruszczyk K, Izidoro JB, Portella MA, Lana AP, Campos Neto OH, Andrade EIG. The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil. Appl Health Econ Health Policy 2021;19:557-77. [PMID: 33506317 DOI: 10.1007/s40258-020-00626-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mulinari S, Vilhelmsson A, Rickard E, Ozieranski P. Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs. PLoS One 2020;15:e0235021. [PMID: 32579571 DOI: 10.1371/journal.pone.0235021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Godman B, Fadare J, Kwon HY, Dias CZ, Kurdi A, Dias Godói IP, Kibuule D, Hoxha I, Opanga S, Saleem Z, Bochenek T, Marković-Peković V, Mardare I, Kalungia AC, Campbell S, Allocati E, Pisana A, Martin AP, Meyer JC. Evidence-based public policy making for medicines across countries: findings and implications for the future. J Comp Eff Res 2021;10:1019-52. [PMID: 34241546 DOI: 10.2217/cer-2020-0273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 van der Schans S, De Loos F, Boersma C, Postma MJ, Büller H. A novel perspective on pharmaceutical R&D costs: opportunities for reductions. Expert Rev Pharmacoecon Outcomes Res 2021;:1-9. [PMID: 34595997 DOI: 10.1080/14737167.2022.1987219] [Reference Citation Analysis]
11 Lopes LC, Godman B, Bergamaschi CC, Barberato-Filho S, Silva MT. Editorial: New Horizons in Health-Promoting Technologies: From Development to Rational Use. Front Pharmacol 2020;11:1180. [PMID: 32848783 DOI: 10.3389/fphar.2020.01180] [Reference Citation Analysis]
12 Faleiros DR, Alvares-Teodoro J, Nunes da Silva E, Godman BB, Gonçalves Pereira R, Gurgel Andrade EI, de Assis Acurcio FA, Guerra Júnior AA. Budget impact analysis of medicines: estimated values versus real-world evidence and the implications. Expert Rev Pharmacoecon Outcomes Res 2021;:1-11. [PMID: 33971778 DOI: 10.1080/14737167.2021.1927716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Miljković N, van Overbeeke E, Godman B, Kovačević M, Anastasi A, Bochenek T, Huys I, Miljković B. Practical Implications From European Hospital Pharmacists on Prospective Risk Assessment for Medicine Shortages. Front Med (Lausanne) 2020;7:407. [PMID: 32850907 DOI: 10.3389/fmed.2020.00407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tsekov I, Dimitrova M, Voynikov Y. Role of the EMA specific marketing authorization procedures for early access on the time to patient access in Bulgaria. PHAR 2021;68:421-5. [DOI: 10.3897/pharmacia.68.e64931] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]